Table 2.

Agents for anti-IGF-1R-based cancer treatment

Name	Target	Mechanism	Current status
Small moelcule inhibitors
INSM-18	IGF-1R and HER2	Substrate competitive inhibitor	Phase I[44]
NVP-AEW541	IGF-1R	ATP-competitive inhibitor	Preclinical[63]
NVP-ADW742	IGF-1R	ATP-competitive inhibitor, activation of proapoptotic pathways	Preclinical[62]
BMS-536924	IGF1R and IR	ATP competitive inhibitor,	Preclinical[143]
Cyclolignans	IGFR-1R	IGF competitive inhibitor	Preclinical[144]
Antibodies
CP-751, 871	IGF-1R	IGF1R downregulation	PhaseIfor multiple myeloma
			Phase II for Breast-[145], lung-[146], and prostate[147] cancer
A12	IGF-1R	IGF1R down-regulation, apoptosis, cell cycle arrest	Phase I[148]
scFv-Fc	IGF-1R	IGF1R downregulation	Preclinical[149]
AVE-1642	IGF-1R	IGF1R downregulation, cell-cycle arrest, induction of apoptosis	Preclinical[69]